Amphastar (AMPH) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

Core Viewpoint - Amphastar Pharmaceuticals reported a revenue of $186.52 million for the quarter ended December 2024, marking a year-over-year increase of 4.7% but falling short of the Zacks Consensus Estimate by 1.08% [1] Financial Performance - The earnings per share (EPS) for the same period was $0.92, compared to $0.88 a year ago, indicating a positive year-over-year growth [1] - The EPS surprise was -4.17%, as the consensus estimate was $0.96 [1] Key Metrics - Amphastar's stock has returned -14.3% over the past month, while the Zacks S&P 500 composite has changed by -2.2% [3] - The company currently holds a Zacks Rank 4 (Sell), suggesting potential underperformance against the broader market in the near term [3] Revenue Breakdown - Primatene MIST: $28.94 million vs. $29.02 million estimate [4] - Epinephrine: $18.70 million vs. $18.93 million estimate [4] - Lidocaine: $14.40 million vs. $14.92 million estimate [4] - Naloxone: $3.60 million vs. $3.72 million estimate [4] - Glucagon: $25.62 million vs. $25.99 million estimate [4] - Enoxaparin: $3.73 million vs. $6.07 million estimate [4] - Phytonadione: $11.17 million vs. $10.55 million estimate [4]